Mirum Pharmaceuticals, Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$6.3M
Doctors Paid
1,634
Transactions
5,705
2024 Total
$2.9M
Payment Breakdown by Category
Research$4.1M (65.4%)
Consulting$1.6M (25.0%)
Travel$323,189 (5.2%)
Food & Beverage$182,336 (2.9%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $4.1M | 798 | 65.4% |
| Consulting Fee | $1.6M | 581 | 25.0% |
| Travel and Lodging | $323,189 | 710 | 5.2% |
| Food and Beverage | $182,336 | 3,558 | 2.9% |
| Grant | $50,000 | 1 | 0.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $41,266 | 10 | 0.7% |
| Education | $736.26 | 42 | 0.0% |
| Entertainment | $373.86 | 4 | 0.0% |
| Compensation for serving as faculty or as a speaker for a medical education program | $350.00 | 1 | 0.0% |
Payments by Type
Research
$4.1M
798 transactions
General
$2.2M
4,907 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| Evaluation of Maralixibat in Biliary Atresia Response Post-Kasai (EMBARK) | $781,399 | 0 | 142 |
| An Extension Study of Maralixibat in Patients with Progressive Familial Intrahepatic Cholestasis (PFIC) (MARCH-ON) | $672,154 | 0 | 194 |
| A Study to Evaluate the Safety and Tolerability of Maralixibat in Infant Participants with Cholestatic Liver Diseases Including Progressive Familial Intrahepatic Cholestasis (PFIC) and Alagille Syndrome (ALGS) (RISE) | $585,733 | 0 | 74 |
| A PHASE 3 STUDY TO EVALUATE THE EFFECTS OF CHENODAL IN ADULT AND PEDIATRIC PATIENTS WITH CEREBROTENDINOUS XANTHOMATOSIS (RESTORE) | $568,994 | 0 | 26 |
| A Long-Term Safety Study of Maralixibat in the Treatment of Cholestatic Liver Disease in Subjects who Previously Participated in a Maralixibat Study (MERGE) | $438,692 | 0 | 83 |
| A Study to Evaluate the Efficacy and Safety of Maralixibat in Subjects with Progressive Familial Intrahepatic Cholestasis (MARCH-PFIC) | $332,765 | 0 | 73 |
| A Prospective, Observational, Non-Interventional, Post-Marketing, Patient Registry to Collect Data on Routine Clinical Care in Patients Treated With Cholbam (Cholic Acid) (REPLACE) | $256,890 | 1 | 132 |
| An Open-Label Study to Evaluate the Safety and Tolerability of Volixibat in Patients with Primary Biliary Cholangitis Currently Being Treated with Obeticholic Acid | $193,680 | 0 | 44 |
| Long-Term SafEty and Clinical Outcomes of LivmArli in Patients with Alagille Syndrome (LEAP) | $172,406 | 0 | 26 |
| A Maralixibat Expanded Access Program for Patients with Cholestatic Pruritus Associated with Alagille Syndrome (ALGS EAP) | $61,300 | 0 | 3 |
| Evaluation of Maralixibat in Pruritus Associated with General Cholestatic Liver Disease (EXPAND) | $31,000 | 0 | 1 |
Payments by Medical Specialty
Top Paid Doctors — Page 2
| Doctor | Specialty | Location | Total | 2024 |
|---|---|---|---|---|
| Patricio Arias, Md, MD | Pediatric Gastroenterology | New Orleans, LA | $18,308 | $0 |
| Dr. Robert Brown, Md, MD | Hepatology | New York, NY | $18,202 | $0 |
| Amber Hildreth, D.o, D.O | Pediatric Transplant Hepatology | San Diego, CA | $17,056 | $0 |
| Nanda Kerkar, M.d, M.D | Transplant Surgery | Rochester, NY | $16,740 | $0 |
| Shikha Sundaram, Md, MD | Pediatric Gastroenterology | Aurora, CO | $16,053 | $0 |
| Dr. Rohit Kohli, Mbbs, Ms, MBBS, MS | Pediatric Gastroenterology | Los Angeles, CA | $16,031 | $0 |
| Linda Book | Pediatric Gastroenterology | Salt Lake City, UT | $15,680 | $0 |
| Ronald Sokol, Md, MD | Pediatric Gastroenterology | Aurora, CO | $15,564 | $0 |
| Janaina Anderson, M.d, M.D | Pediatric Gastroenterology | Charleston, SC | $15,217 | $0 |
| Ruben Quiros, M.d, M.D | Gastroenterology | Houston, TX | $15,010 | $0 |
| Naveen Mittal, Md, MD | Pediatric Gastroenterology | Dallas, TX | $14,546 | $0 |
| Kathleen Loomes, M.d, M.D | Pediatrics | Philadelphia, PA | $14,076 | $0 |
| Dr. Amal Aqul, Md, MD | Pediatrics | Dallas, TX | $13,857 | $0 |
| Vera Hupertz, M.d, M.D | Pediatric Gastroenterology | Cleveland, OH | $13,438 | $0 |
| Miss. Alyssa Kriegermeier, M.d, M.D | Pediatric Gastroenterology | Chicago, IL | $13,228 | $0 |
| Unknown Provider | — | — | $13,200 | $0 |
| Elizabeth Mileti, Do, DO | Student in an Organized Health Care Education/Training Program | Las Vegas, NV | $13,153 | $0 |
| Dr. Udeme Ekong, M.d, M.D | Pediatric Gastroenterology | New Haven, CT | $12,612 | $0 |
| Dr. Brian Edelstein, M.d, M.D | Pediatric Gastroenterology | Buffalo, NY | $12,214 | $0 |
| Paul Duell, Md, MD | Endocrinology, Diabetes & Metabolism | Portland, OR | $11,949 | $0 |
| Dr. Katherine Mcgoogan, Md, MD | Pediatrics | Jacksonville, FL | $11,735 | $0 |
| Richard Green, Md, MD | Hepatology | Chicago, IL | $11,687 | $0 |
| John Bucuvalas, M.d, M.D | Pediatric Gastroenterology | New York, NY | $11,205 | $0 |
| Dr. Akihiro Asai, M.d., Ph.d, M.D., PH.D | Pediatric Gastroenterology | Cincinnati, OH | $11,071 | $0 |
| Aymin Delgado, M.d, M.D | Pediatrics | Naples, FL | $10,647 | $0 |
About Mirum Pharmaceuticals, Inc.
Mirum Pharmaceuticals, Inc. has made $6.3M in payments to 1,634 healthcare providers, recorded across 5,705 transactions in the CMS Open Payments database. In 2024, the company paid $2.9M. The top product by payment volume is Livmarli ($4.1M).
Payments were distributed across 94 medical specialties. The top specialty by payment amount is Pediatric Gastroenterology ($779,526 to 343 doctors).
Payment categories include: Food & Beverage ($182,336), Consulting ($1.6M), Research ($4.1M), Travel & Lodging ($323,189).
Mirum Pharmaceuticals, Inc. is associated with 1 products in the CMS Open Payments database.